These findings establish a novel, non-canonical function of the IRE1/Xbp1 branch in modulating pathogenic DPR burden and highlight its potential as a therapeutic target for ALS and FTD. This evidence concerns the gene XBP1 and amyotrophic lateral sclerosis.